Five Decisions to Make Before Scaling AI in MLR Review

A successful demonstration can show that an AI system finds issues in a medical content material. It cannot show whether the system is ready to operate across teams, markets, repositories, and formal review workflows.

Before expanding a pilot, the MLR transformation sponsor must align business owners, reviewers, Quality, IT, and vendors on what the system may do, which sources it may trust, who can override it, and which control path its intended use requires.

The safest way to scale AI in MLR is to define the task, govern the evidence, and preserve human decision rights before expanding scope.

The five decisions below turn that principle into an operating model.

The five decisions at a glance

Decision 1: Build, buy, or combine both

"Build versus buy" is often treated as a technology procurement question. In MLR, it is also a question about where the organization wants to retain knowledge, control, and accountability.

An internal build can offer deep customization and direct control over architecture, data handling, and releases. It also makes the organization responsible for the full operating stack, evaluation, change control, access management, monitoring, and support.

A specialized platform can reduce the infrastructure a team must create. But buyers still need to examine deployment, data use, isolation, auditability, integration, configuration ownership, validation support, change notification, and exit planning.

For many organizations, the practical answer is hybrid. The company retains control of approved claims, evidence, company-specific SOPs, decision records, access rules, and final workflow authority while using a vendor for selected review and infrastructure capabilities.

The decision should follow four questions:

• Is the capability a source of strategic differentiation or a repeatable platform function?
• Can the organization staff and maintain it across the full lifecycle?
• Can each important output be traced to controlled evidence and a known system version?
• Can the organization change vendors or components without losing its governed knowledge and decision history?

Data sovereignty is not only where files are stored. It is also who controls the evidence model, permissions, versions, and downstream use of the output.

Decision 2: Start with one bounded task or the full chain

An end-to-end vision can help stakeholders align. It is rarely a useful first production scope.

"Review the entire material" combines tasks with different evidence, error costs, owners, and acceptance criteria—from references and claims to privacy, disclaimers, and visual context. A single overall accuracy score hides those differences.

A better first deployment has a narrow context of use. For example:

The system identifies possible claim-reference mismatches in HCP-facing slide decks before formal MLR approval. It shows the claim, source candidate, page location, and comparison rationale. A qualified Medical reviewer decides whether the evidence is adequate.

The first task should be bounded, but not trivial. Choose a frequent problem with inspectable evidence and an action a reviewer can confirm. Define false-positive and false-negative consequences before the pilot.

Expansion should follow gates: acceptable task performance, stable evidence retrieval, usable reviewer output, documented overrides, and an owner for unresolved cases. The roadmap may be broad; the first operational promise should remain precise.

Decision 3: Decide what evidence is ready for machine use

"Data governance first" is directionally correct, but it can become an endless cleanup program. Teams do not need to normalize every repository before learning. They need a governed evidence slice for the first context of use.

For a claim-reference task, that slice might include:

• approved claim wording and permitted variants;
• source passages, tables, figures, and product information;
• product, indication, population, endpoint, audience, market, and channel constraints;
• effective dates, approval status, and version history;
• applicable company-specific SOPs and decision rules;
• access rights, provenance, and retention requirements.

Historical review decisions can add valuable context, but they should not be treated as automatic ground truth. Older records may reflect superseded policies, inconsistent reviewer practice, incomplete rationale, or a different market and audience. Before reuse, teams should classify which decisions remain authoritative, which are examples, and which should be excluded.

Connecting a literature database does not make its evidence controlled. The system must preserve source identity, version, retrieval date, access conditions, and the exact passage or object used for a flag.

A model cannot compensate for an evidence layer that does not distinguish current, applicable, and merely available information.

Decision 4: Redesign the reviewer operating model

Telling reviewers that AI will not replace them is not enough. The workflow must prove it.

A useful operating model defines:

• which issues AI may identify, prioritize, or route;
• what evidence and rationale reviewers see;
• when the system must abstain because evidence is missing or conflicting;
• who can accept, reject, or modify a finding;
• how override reasons are recorded;
• which issues require escalation and to whom;
• who monitors performance and approves changes to rules or models.

This shifts the reviewer from searching disconnected sources toward assessing prepared evidence. It does not remove routine work automatically; it makes the division of work visible and measurable.

Reviewer feedback should improve the system without silently rewriting policy. An override may reveal a model error, missing source, ambiguous SOP, or valid exception. These events need different routes, or the system may reproduce inconsistency.

Human oversight is meaningful only when the reviewer has time, context, authority, and a documented way to disagree.

Decision 5: Match quality and regulatory engagement to the context of use

The original implementation question should not be "Is this AI GxP?" It should be: What decision does the system support, what record does it create, and what happens when it is wrong?

The answer determines the control path. An internal tool that flags candidates for a qualified reviewer is not automatically equivalent to AI that generates submission evidence, controls manufacturing, or functions as a medical device. Obligations depend on jurisdiction, intended use, system boundaries, data, and downstream action.

Official regulatory pathways are also context-specific. FDA encourages early engagement for AI used in drug development and identifies different channels according to intended use. Its Q-Submission and Pre-Submission programs are primarily device pathways; drug sponsors use appropriate formal meetings and specialized programs. EMA offers scientific advice and qualification procedures for technologies and novel methodologies used in medicine development. These channels should not be presented as one universal route for every internal MLR tool.

Before seeking external advice, an organization should be able to explain:

1. the intended context of use;
2. the decision or workflow action influenced by the output;
3. the controlled inputs and evidence;
4. the human review and escalation path;
5. the evaluation plan, known limitations, and change controls.

Quality, regulatory, privacy, security, and legal teams should classify the use early. External engagement can reduce uncertainty when a relevant pathway applies, but the first governance act is to define the use precisely enough to know which pathway applies.

A controlled sequence from pilot to scale

The five decisions work best as a sequence:

1. Define one review task. Name the material, review point, evidence, output, decision owner, and excluded uses.
2. Choose the sourcing model. Decide which knowledge, controls, and infrastructure the organization must own.
3. Prepare the evidence slice. Curate the minimum claims, sources, SOPs, versions, and permissions needed for the task.
4. Run a measured pilot. Evaluate by material type and review point; inspect errors, abstentions, overrides, and reviewer usefulness.
5. Approve expansion deliberately. Add a task, market, or material type only after its evidence, owner, controls, and acceptance criteria are defined.

This is slower than promising an instant end-to-end transformation. It is faster than discovering after rollout that teams disagree about what the system was allowed to do.

Where ZENO fits

ZENO is designed as an MLR pre-review layer for medical content materials before formal MLR approval.

It supports teams by helping identify and locate potential review risks, connect findings to evidence and company-specific review logic, explain why an issue was flagged, and route it to the appropriate human reviewer. The system does not own the final Medical, Legal, Regulatory, or Compliance decision.

That position supports a controlled transformation path: start with a defined review task, produce human-reviewable output, measure how the workflow performs, and expand only when the next context of use is ready.